HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Developing Reviewer Communications Policy; Draft Expected This Year

Executive Summary

FDA is drafting an internal policy on communication with sponsors that will address some of the issues raised during the House Energy & Commerce Committee hearing into the handling of ImClone's BLA for Erbitux
Advertisement

Related Content

Clinical Trial Race, Ethnicity Categories Should Match OMB’s, FDA Says
Clinical Trial Race, Ethnicity Categories Should Match OMB’s, FDA Says
FDA Emphasizing Written Communication With Sponsors On Pending NDAs
FDA Emphasizing Written Communication With Sponsors On Pending NDAs
Erbitux Hearing May Feature FDA Reviewer Communication Policies
Erbitux Inquiry Could Yield Pre-Approval Speech Bill – Rep. Greenwood
CDER Review “Consistency” Is One Theme Of FDA Reorganization
Erbitux Hearing Puts Focus On Pre-Approval Promotion, FDA Communication
PDUFA III “Good Review Management Principles” To Stress Early Action
PDUFA III “Good Review Management Principles” To Stress Early Action
Advertisement
UsernamePublicRestriction

Register

PS040498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel